Clinical Trial Update: Safety and Effectiveness of BMS-986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and effectiveness of BMS-986263 in adults with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cirrhosis
• Nonalcoholic Steatohepatitis

Drugs mentioned

• BMS-986263

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Nonalcoholic Steatohepatitis (NASH) | Phase 2 | Status: TERMINATED | Results posted: 2024-09-04